233 related articles for article (PubMed ID: 19902985)
41. The aetiology of oligomenorrhoea and/or hirsuties: a study of 467 patients.
Ferriman D; Purdie AW
Postgrad Med J; 1983 Jan; 59(687):17-20. PubMed ID: 6866869
[TBL] [Abstract][Full Text] [Related]
42. A genetic risk score is associated with polycystic ovary syndrome-related traits.
Lee H; Oh JY; Sung YA; Chung HW
Hum Reprod; 2016 Jan; 31(1):209-15. PubMed ID: 26573528
[TBL] [Abstract][Full Text] [Related]
43. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.
Pirwany IR; Yates RW; Cameron IT; Fleming R
Hum Reprod; 1999 Dec; 14(12):2963-8. PubMed ID: 10601079
[TBL] [Abstract][Full Text] [Related]
44. Spuriously high androstendione concentrations due to assay interference as a cause of diagnostic conundrum in women with oligomenorrhoea.
Lewandowski KC; Grotowski W; Dabrowska K; Głowacka E; Lewiński A
Ginekol Pol; 2015 Mar; 86(3):229-33. PubMed ID: 25920315
[TBL] [Abstract][Full Text] [Related]
45. Changes in the PCOS phenotype with age.
Hsu MI
Steroids; 2013 Aug; 78(8):761-6. PubMed ID: 23624031
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study.
Taponen S; Ahonkallio S; Martikainen H; Koivunen R; Ruokonen A; Sovio U; Hartikainen AL; Pouta A; Laitinen J; King V; Franks S; McCarthy MI; Järvelin MR
Hum Reprod; 2004 May; 19(5):1083-8. PubMed ID: 15044401
[TBL] [Abstract][Full Text] [Related]
47. Polycystic ovary syndrome: a common but often unrecognized condition.
Shannon M; Wang Y
J Midwifery Womens Health; 2012; 57(3):221-30. PubMed ID: 22594862
[TBL] [Abstract][Full Text] [Related]
48. Reduced bone mineral density in adult women diagnosed with menstrual disorders during adolescence.
Wiksten-Almströmer M; Hirschberg AL; Hagenfeldt K
Acta Obstet Gynecol Scand; 2009; 88(5):543-9. PubMed ID: 19353333
[TBL] [Abstract][Full Text] [Related]
49. Variation of luteinizing hormone and androgens in oligomenorrhoea and its implications for the study of polycystic ovary syndrome.
van Hooff MH; van der Meer M; Lambalk CB; Schoemaker J
Hum Reprod; 1999 Jul; 14(7):1684-9. PubMed ID: 10402368
[TBL] [Abstract][Full Text] [Related]
50. Polycystic ovary syndrome in adolescents.
Dabadghao P
Best Pract Res Clin Endocrinol Metab; 2019 Jun; 33(3):101272. PubMed ID: 31027973
[TBL] [Abstract][Full Text] [Related]
51. Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents.
Villarroel C; López P; Merino PM; Iñiguez G; Sir-Petermann T; Codner E
Gynecol Endocrinol; 2015; 31(8):625-9. PubMed ID: 26190534
[TBL] [Abstract][Full Text] [Related]
52. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI
J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641
[TBL] [Abstract][Full Text] [Related]
53. The prevalence of polycystic ovaries in thin oligomenorrhoeic, anovulatory women.
Eden JA; Place J
Aust N Z J Obstet Gynaecol; 1989 Feb; 29(1):70-1. PubMed ID: 2787631
[TBL] [Abstract][Full Text] [Related]
54. A practical guide to the diagnosis and management of amenorrhoea.
Crosignani PG; Vegetti W
Drugs; 1996 Nov; 52(5):671-81. PubMed ID: 9118817
[TBL] [Abstract][Full Text] [Related]
55. Aromatase inhibitors for subfertile women with polycystic ovary syndrome.
Franik S; Kremer JA; Nelen WL; Farquhar C
Cochrane Database Syst Rev; 2014 Feb; (2):CD010287. PubMed ID: 24563180
[TBL] [Abstract][Full Text] [Related]
56. 12-months of increased dietary intake does not exacerbate disordered eating-related attitudes, stress, or depressive symptoms in women with exercise-associated menstrual disturbances: The REFUEL randomized controlled trial.
Strock NCA; De Souza MJ; Mallinson RJ; Olmsted M; Allaway HCM; O'Donnell E; Plessow F; Williams NI
Psychoneuroendocrinology; 2023 Jun; 152():106079. PubMed ID: 36947969
[TBL] [Abstract][Full Text] [Related]
57. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Tang T; Lord JM; Norman RJ; Yasmin E; Balen AH
Cochrane Database Syst Rev; 2012 May; (5):CD003053. PubMed ID: 22592687
[TBL] [Abstract][Full Text] [Related]
58. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome.
Elting MW; Korsen TJ; Schoemaker J
Clin Endocrinol (Oxf); 2001 Dec; 55(6):767-76. PubMed ID: 11895219
[TBL] [Abstract][Full Text] [Related]
59. Effect of polycystic ovary syndrome on cardiac autonomic function at a late fertile age: a prospective Northern Finland Birth Cohort 1966 study.
Ollila MM; Kiviniemi A; Stener-Victorin E; Tulppo M; Puukka K; Tapanainen J; Franks S; Morin-Papunen L; Piltonen T
BMJ Open; 2019 Dec; 9(12):e033780. PubMed ID: 31843853
[TBL] [Abstract][Full Text] [Related]
60. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.
Harris HR; Babic A; Webb PM; Nagle CM; Jordan SJ; Risch HA; Rossing MA; Doherty JA; Goodman MT; Modugno F; Ness RB; Moysich KB; Kjær SK; Høgdall E; Jensen A; Schildkraut JM; Berchuck A; Cramer DW; Bandera EV; Wentzensen N; Kotsopoulos J; Narod SA; Phelan CM; McLaughlin JR; Anton-Culver H; Ziogas A; Pearce CL; Wu AH; Terry KL; ;
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):174-182. PubMed ID: 29141849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
